摘要
目的：为了解ＢＣＧＣＷＳ（细胞壁骨架）对膀胱局部免疫抗肿瘤机理而进行研究。方法：通过酶联免疫吸附法（ＥＬＩＳＡ），检测浅表膀胱癌患者ＢＣＧＣＷＳ灌注后，尿中细胞因子（ＩＬ２和ＴＮＦα）的变化情况。结果：ＩＬ２灌注前（３６．９±１５．９）ｎｇ／Ｌ，灌注后（１５４．０±３１９）ｎｇ／Ｌ；ＴＮＦα灌注前（４７８±２４１）μｇ／Ｌ，灌注后（６０９９±２３９８）μｇ／Ｌ。灌注前后比较有显著性差异（Ｐ＜０００１）。结论：ＢＣＧＣＷＳ能激活巨噬细胞致敏淋巴细胞分泌细胞因子ＩＬ２和ＴＮＦα，发挥局部免疫抗肿瘤作用。
Objective:To address the antitumor mechanism and to monitor the immunological response of patients following interavesical (BCGCWS eleton) treatment.Methods:The local secretion of IL2 and TNFα was examined in the urine of patients before and after intravesical instillation of BCGCWS. By using an enzymelinked immunosorbant assay (ELISA) technique to determine the levels of cytokines the difference between pre and postCWS mean urinary levels of IL2 and TNFα. Results:It showed that the levels of IL2 and TNFα increased significantly from (36.9±15.9) ng/L and (47.8±24.1) μg/L to (154.0±31.9) ng/L and (609.9±239.8) μg/L, respectively (P<0.001).Conclusions:The BCGCWS can induce T lymphocytes and actiwated macrophages to cytokines in response to a specific antiginic stimulation. Prophylactic intravesical treatment with BCGCWS is an effective therapy method for recurrent superficial bladder carcinoma.
出处
《中山大学学报（医学科学版）》
CAS
CSCD
1998年第S1期5-7,共3页
Journal of Sun Yat-Sen University:Medical Sciences
基金
卫生部科研基金
